Cost of migration: invasion of malignant gliomas and implications for treatment - PubMed (original) (raw)
Review
. 2003 Apr 15;21(8):1624-36.
doi: 10.1200/JCO.2003.05.063.
Affiliations
- PMID: 12697889
- DOI: 10.1200/JCO.2003.05.063
Review
Cost of migration: invasion of malignant gliomas and implications for treatment
A Giese et al. J Clin Oncol. 2003.
Abstract
Tumors of glial origin consist of a core mass and a penumbra of invasive, single cells, decreasing in numbers towards the periphery and still detectable several centimeters away from the core lesion. Several decades ago, the diffuse nature of malignant gliomas was recognized by neurosurgeons when super-radical resections using hemispherectomies failed to eradicate these tumors. Local invasiveness eventually leads to regrowth of a recurrent tumor predominantly adjacent to the resection cavity, which is not significantly altered by radiation or chemotherapy. This raises the question of whether invasive glioma cells activate cellular programs that render these cells resistant to conventional treatments. Clinical and experimental data demonstrate that glioma invasion is determined by several independent mechanisms that facilitate the spread of these tumors along different anatomic and molecular structures. A common denominator of this cellular behavior may be cell motility. Gene-expression profiling showed upregulation of genes related to motility, and functional studies demonstrated that cell motility contributes to the invasive phenotype of malignant gliomas. There is accumulating evidence that invasive glioma cells show a decreased proliferation rate and a relative resistance to apoptosis, which may contribute to chemotherapy and radiation resistance. Interestingly, interference with cell motility by different strategies results in increased susceptibility to apoptosis, indicating that this dynamic relationship can potentially be exploited as an anti-invasive treatment paradigm. In this review, we discuss mechanisms of glioma invasion, characteristics of the invasive cell, and consequences of this cellular phenotype for surgical resection, oncologic treatments, and future perspectives for anti-invasive strategies.
Similar articles
- Possible future issues in the treatment of glioblastomas: special emphasis on cell migration and the resistance of migrating glioblastoma cells to apoptosis.
Lefranc F, Brotchi J, Kiss R. Lefranc F, et al. J Clin Oncol. 2005 Apr 1;23(10):2411-22. doi: 10.1200/JCO.2005.03.089. J Clin Oncol. 2005. PMID: 15800333 Review. - BCL-xL: time-dependent dissociation between modulation of apoptosis and invasiveness in human malignant glioma cells.
Weiler M, Bähr O, Hohlweg U, Naumann U, Rieger J, Huang H, Tabatabai G, Krell HW, Ohgaki H, Weller M, Wick W. Weiler M, et al. Cell Death Differ. 2006 Jul;13(7):1156-69. doi: 10.1038/sj.cdd.4401786. Epub 2005 Oct 28. Cell Death Differ. 2006. PMID: 16254573 - Autocrine factors that sustain glioma invasion and paracrine biology in the brain microenvironment.
Hoelzinger DB, Demuth T, Berens ME. Hoelzinger DB, et al. J Natl Cancer Inst. 2007 Nov 7;99(21):1583-93. doi: 10.1093/jnci/djm187. Epub 2007 Oct 30. J Natl Cancer Inst. 2007. PMID: 17971532 Review. - Therapeutic strategies for inhibiting invasion in glioblastoma.
Drappatz J, Norden AD, Wen PY. Drappatz J, et al. Expert Rev Neurother. 2009 Apr;9(4):519-34. doi: 10.1586/ern.09.10. Expert Rev Neurother. 2009. PMID: 19344303 - Related to testes-specific, vespid, and pathogenesis protein-1 (RTVP-1) is overexpressed in gliomas and regulates the growth, survival, and invasion of glioma cells.
Rosenzweig T, Ziv-Av A, Xiang C, Lu W, Cazacu S, Taler D, Miller CG, Reich R, Shoshan Y, Anikster Y, Kazimirsky G, Sarid R, Brodie C. Rosenzweig T, et al. Cancer Res. 2006 Apr 15;66(8):4139-48. doi: 10.1158/0008-5472.CAN-05-2851. Cancer Res. 2006. PMID: 16618735
Cited by
- CD57 defines a novel cancer stem cell that drive invasion of diffuse pediatric-type high grade gliomas.
Qi L, Du Y, Huang Y, Kogiso M, Zhang H, Xiao S, Abdallah A, Suarez M, Niu L, Liu ZG, Lindsay H, Braun FK, Stephen C, Davies PJ, Teo WY, Adenkunle A, Baxter P, Su JM, Li XN. Qi L, et al. Br J Cancer. 2024 Jul;131(2):258-270. doi: 10.1038/s41416-024-02724-5. Epub 2024 Jun 4. Br J Cancer. 2024. PMID: 38834745 - Novel cancer-fighting role of ticagrelor inhibits GTSE1-induced EMT by regulating PI3K/Akt/NF-κB signaling pathway in malignant glioma.
Lu E, Zhao B, Yuan C, Liang Y, Wang X, Yang G. Lu E, et al. Heliyon. 2024 May 7;10(9):e30833. doi: 10.1016/j.heliyon.2024.e30833. eCollection 2024 May 15. Heliyon. 2024. PMID: 38774096 Free PMC article. - Targeting Integrin α3 Blocks β1 Maturation, Triggers Endoplasmic Reticulum Stress, and Sensitizes Glioblastoma Cells to TRAIL-Mediated Apoptosis.
Kuranaga Y, Yu B, Osuka S, Zhang H, Devi NS, Bae S, Van Meir EG. Kuranaga Y, et al. Cells. 2024 Apr 26;13(9):753. doi: 10.3390/cells13090753. Cells. 2024. PMID: 38727288 Free PMC article. - New insights into targeted therapy of glioblastoma using smart nanoparticles.
Ghaznavi H, Afzalipour R, Khoei S, Sargazi S, Shirvalilou S, Sheervalilou R. Ghaznavi H, et al. Cancer Cell Int. 2024 May 7;24(1):160. doi: 10.1186/s12935-024-03331-3. Cancer Cell Int. 2024. PMID: 38715021 Free PMC article. Review. - Viscoelastic high-molecular-weight hyaluronic acid hydrogels support rapid glioblastoma cell invasion with leader-follower dynamics.
Carvalho EM, Ding EA, Saha A, Weldy A, Zushin PH, Stahl A, Aghi MK, Kumar S. Carvalho EM, et al. bioRxiv [Preprint]. 2024 Apr 6:2024.04.04.588167. doi: 10.1101/2024.04.04.588167. bioRxiv. 2024. PMID: 38617333 Free PMC article. Preprint.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical